LEXEO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.01 USD | -26.08% |
|
-20.43% | -3.06% |
| Jul. 15 | Sector Update: Health Care Stocks Retreat Monday Afternoon | MT |
| Jul. 15 | Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 357.6 | 579.8 | - | - |
| Enterprise Value (EV) 1 | 236.1 | 354.9 | 459.4 | 579.8 |
| P/E ratio | -1.08 x | -4.97 x | -4.93 x | -5.3 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -3.46 x | -4.49 x | -5.74 x | -7.07 x |
| EV / FCF | -3.96 x | -4.67 x | -5.1 x | -6.44 x |
| FCF Yield | -25.2% | -21.4% | -19.6% | -15.5% |
| Price to Book | 3.15 x | 2.93 x | 2.39 x | 4.11 x |
| Nbr of stocks (in thousands) | 26,646 | 32,945 | - | - |
| Reference price 2 | 13.42 | 13.01 | 13.01 | 13.01 |
| Announcement Date | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | - | -68.24 | -79 | -80 | -82 |
| EBIT 1 | - | -68.51 | -93.6 | -111.5 | -145.3 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -66.39 | -82.54 | -96.38 | -79.66 |
| Net income 1 | -59.28 | -66.39 | -79.26 | -91.05 | -79.29 |
| Net margin | - | - | - | - | - |
| EPS 2 | -36.34 | -12.40 | -2.617 | -2.638 | -2.455 |
| Free Cash Flow 1 | - | -59.61 | -76 | -90 | -90 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 9/29/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -20.12 | - | -23.22 | -18 | -18 | -19 | - | - |
| EBIT 1 | -20.27 | -14.97 | -23.29 | -22.5 | -23.62 | -25 | -29.25 | -31.5 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -20.11 | -14.19 | -21.68 | -19.78 | -20.15 | -20.53 | -23.98 | -25.58 |
| Net income 1 | -20.11 | -14.19 | -21.68 | -19.25 | -19.49 | -18.57 | -23.98 | -25.58 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.220 | - | -0.7700 | -0.6270 | -0.6229 | -0.5912 | -0.6750 | -0.7100 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/23 | 3/11/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 121 | 225 | 120 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -59.6 | -76 | -90 | -90 |
| ROE (net income / shareholders' equity) | - | -58.5% | -61.9% | -46.2% | -47.2% |
| ROA (Net income/ Total Assets) | - | -56.1% | -51% | -39.9% | -40.8% |
| Assets 1 | - | 118.4 | 155.3 | 228 | 194.6 |
| Book Value Per Share 2 | - | 4.260 | 4.450 | 5.450 | 3.170 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.12 | 2.89 | 2.03 | 2 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 9/29/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.01
USD
Average target price
22.86
USD
Spread / Average Target
+75.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.06% | 580M | |
| +22.15% | 46.55B | |
| +45.94% | 41.84B | |
| -2.37% | 40.84B | |
| +33.84% | 32.95B | |
| -6.35% | 28.27B | |
| +20.42% | 27.78B | |
| +48.83% | 14.26B | |
| +45.00% | 13.69B | |
| +0.06% | 12.18B |
- Stock Market
- Equities
- LXEO Stock
- Financials Lexeo Therapeutics, Inc.
